CytomX Therapeutics CTMX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$59.14M-241% | -$17.37M-162% | $28.02M-41.6% | $47.98M+15.3% | $41.6M+30.5% | ||
| $9M+42.8% | $6.3M-6.0% | $6.71M-8.3% | $7.32M-5.8% | $7.77M+1.3% | ||
| —— | —— | -$1.72M— | —— | —— | ||
| $1.09M+394% | $221K+132% | -$695K— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$31.14M+52.9% | -$66.15M+35.0% | -$101.7M+20.7% | -$128.19M+4.3% | -$133.93M-13.3% | ||
| $147K+0.7% | $146K0.0% | $146K0.0% | $146K0.0% | $146K0.0% | ||
| -$80.09M-6.0% | -$75.59M-4.6% | -$72.25M+6.7% | -$77.43M+4.7% | -$81.23M+5.8% | ||
| —— | —— | —— | $245K-22.0% | $314K+1.3% | ||
| $415.52M+116% | $192.52M-2.8% | $198.09M+3.9% | $190.72M+8.8% | $175.28M+12.7% | ||
| $132.5M-0.4% | $133M-20.8% | $168M-5.9% | $178.5M-31.6% | $261M+2.2% | ||
| -$283.56M-371% | -$60.18M-96.5% | -$30.63M-146% | -$12.46M-115% | $85.41M-14.3% | ||
| $338.01M+208% | $109.66M+14.9% | $95.47M0.0% | $95.47M+1,317% | $6.74M-2.5% | ||
| $344.93M+212% | $110.45M+15.0% | $96.05M+0.3% | $95.8M+1,204% | $7.35M-2.3% | ||
| -$18.28M+26.6% | -$24.89M— | —— | —— | —— | ||
| $2.48M+12.3% | $2.21M-3.0% | $2.27M-20.4% | $2.86M-26.7% | $3.9M-26.6% | ||
| $147K+0.7% | $146K0.0% | $146K0.0% | $146K0.0% | $146K0.0% | ||
| $1.1M-11.0% | $1.23M+8.6% | $1.13M-20.7% | $1.43M-7.3% | $1.54M-5.1% | ||
| —— | -$402K-22.6% | -$328K-29.1% | -$254K-41.1% | -$180K-69.8% | ||
| —— | —— | -$9.09M— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$4.53M-1.1% | -$4.48M-2.4% | -$4.38M-2.4% | -$4.28M-2.4% | -$4.18M-2.3% | ||
| $415.52M+116% | $192.52M-2.8% | $198.09M+3.9% | $190.72M+8.8% | $175.28M+12.7% | ||
| $132.5M-0.4% | $133M-20.8% | $168M-5.9% | $178.5M-31.6% | $261M+2.2% | ||
| $1.09M+34.6% | $811K+32.3% | $613K+70.3% | $360K-18.0% | $439K-28.4% | ||
| —— | —— | —— | —— | —— | ||
| -$31.14M+52.9% | -$66.15M+35.0% | -$101.7M+20.7% | -$128.19M+4.3% | -$133.93M-13.3% | ||
| —— | $3M+33.3% | $2.25M+50.0% | $1.5M+100% | $750.5K— | ||
| —— | —— | —— | —— | —— | ||
| -$80.19M-5.8% | -$75.81M-4.8% | -$72.35M+6.9% | -$77.68M+4.7% | -$81.54M+5.8% | ||
| -$80.19M-5.8% | -$75.81M-4.8% | -$72.35M+6.9% | -$77.68M+4.7% | -$81.54M+5.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does CytomX Therapeutics generate?
- CytomX Therapeutics (CTMX) generated -$80.1M in operating cash flow over the trailing twelve months.
- What is CytomX Therapeutics's free cash flow?
- After $347.0K of capital expenditures, CytomX Therapeutics's free cash flow was -$80.2M over the trailing twelve months, up 1.7% year over year.
- Where does CytomX Therapeutics's cash flow data come from?
- Every line is extracted from CytomX Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
